iRadimed (NASDAQ:IRMD) CEO Roger Susi Sells 3,750 Shares

iRadimed Corporation (NASDAQ:IRMD) CEO Roger Susi sold 3,750 shares of the company’s stock in a transaction that occurred on Monday, May 4th. The stock was sold at an average price of $85.69, for a total value of $321,337.50. Following the transaction, the chief executive officer directly owned 2,191,250 shares in the company, valued at $187,768,212.50. The trade was a 0.17% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

iRadimed Price Performance

Shares of NASDAQ:IRMD traded up $0.34 during trading on Wednesday, reaching $86.20. 39,699 shares of the stock were exchanged, compared to its average volume of 87,238. The firm has a market cap of $1.10 billion, a price-to-earnings ratio of 47.10 and a beta of 0.90. The stock has a fifty day moving average of $96.34 and a two-hundred day moving average of $94.26. iRadimed Corporation has a 1-year low of $50.61 and a 1-year high of $107.90.

iRadimed (NASDAQ:IRMD) last posted its quarterly earnings data on Friday, May 1st. The medical equipment provider reported $0.49 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.46 by $0.03. iRadimed had a net margin of 27.36% and a return on equity of 24.48%. The firm had revenue of $21.98 million for the quarter, compared to the consensus estimate of $21.32 million. iRadimed has set its FY 2026 guidance at 2.060-2.210 EPS and its Q2 2026 guidance at 0.440-0.480 EPS. Sell-side analysts forecast that iRadimed Corporation will post 1.94 EPS for the current year.

iRadimed Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, May 29th. Shareholders of record on Friday, May 15th will be given a $0.20 dividend. This represents a $0.80 dividend on an annualized basis and a yield of 0.9%. The ex-dividend date of this dividend is Friday, May 15th. iRadimed’s dividend payout ratio is presently 43.72%.

Institutional Investors Weigh In On iRadimed

Several large investors have recently modified their holdings of IRMD. Principal Financial Group Inc. lifted its stake in iRadimed by 14.7% in the first quarter. Principal Financial Group Inc. now owns 9,732 shares of the medical equipment provider’s stock valued at $937,000 after purchasing an additional 1,245 shares during the last quarter. Fifth Third Bancorp bought a new position in iRadimed during the first quarter valued at $198,000. Y Intercept Hong Kong Ltd bought a new position in iRadimed during the first quarter valued at $334,000. Inspire Investing LLC bought a new position in iRadimed during the first quarter valued at $107,000. Finally, SG Americas Securities LLC grew its holdings in iRadimed by 4.5% during the first quarter. SG Americas Securities LLC now owns 73,561 shares of the medical equipment provider’s stock valued at $7,081,000 after purchasing an additional 3,170 shares during the period. Hedge funds and other institutional investors own 92.34% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have commented on IRMD shares. Lake Street Capital reissued a “buy” rating and set a $120.00 target price on shares of iRadimed in a research report on Wednesday, February 11th. Freedom Capital raised iRadimed to a “strong-buy” rating in a research report on Thursday, April 2nd. Finally, Roth Mkm reiterated a “buy” rating and set a $120.00 price target on shares of iRadimed in a report on Tuesday, February 10th. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of $120.00.

iRadimed Company Profile

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.